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BACKGROUND: A striking efficiency of interferon (IFN)-based anticancer therapy for advanced hepatocellular carcinoma (HCC) has
been reported. Because its clinical efficiency greatly depends on each patient’s local response, prediction of local response is crucial.
METHODS: Continuous exposure of IFN-a to parental PLC/PRF/5 cells (PLC-P) and a limiting dilution method resulted in the
establishment of IFN-resistant cell clones (PLC-Rs). Microarray analyses of PLC-P and PLC-Rs identified insulin-like growth
factor-binding protein 7 (IGFBP7) as one of the most significantly downregulated genes in PLC-Rs. Changes in anticancer effects of
IFN-a were examined in HCC cells after genetic manipulation of IGFBP7 expression. The correlation between immunohisto-
chemically determined IGFBP7 expression and the response to IFN-a/5-fluorouracil (5-FU) therapy was investigated in surgically
resected HCC specimens.
RESULTS: PLC-R cells showed a remarkable downregulation of IGFBP7 and resistance to IFN-a, compared with PLC-P. Parental PLC/
PRF/5 cells transfected with short hairpin RNA against IGFBP7 showed a significant resistance to IFN-a relative to control cells (IC50
fold increase¼14.38 times). Insulin-like growth factor-binding protein 7 transfection into PLC-R restored sensitivity to IFN-a.I n
resected specimens, IGFBP7 expression significantly correlated with the response to IFN-a/5-FU therapy.
CONCLUSION: IGFBP7 could be a useful predictor of the response to IFN-based therapy in advanced HCC.
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The prognosis of patients with advanced hepatocellular carcinoma
(HCC) remains poor, particularly in patients with tumour thrombi
in the major trunk of the portal vein, even after curative resection
of the tumour (Tanaka et al, 1996; Yamakado et al, 1999; Asahara,
1999 no. 47). In such a situation, conventional therapies have no
clinical impact because of poor efficacy and possible complications
(Furuse et al, 1997; Lee et al, 1997). Therefore, a new strategy is
required for patients with advanced HCC.
Several studies have reported strong antitumour activity of
interferon (IFN)-based combination chemotherapy to HCC,
irrespective of the lack of satisfactory results of IFN-a mono-
therapy (Urabe et al, 1998; Leung et al, 1999; Chung et al, 2000;
Patt et al, 2003; Obi et al, 2006). We have also reported the clinical
efficiency of IFN-a and 5-fluorouracil (5-FU) (IFN-a/5-FU) therapy
for advanced HCC and the underlying mechanisms of antitumour
effects (Eguchi et al, 2000; Kondo et al, 2000, 2005; Sakon et al,
2002; Yamamoto et al, 2004; Ota et al, 2005; Nakamura et al, 2007;
Wada et al, 2007, 2009; Damdinsuren et al, 2007a,b; Nagano et al,
2007a,b). These previous studies showed that IFN-a suppresses the
proliferation of HCC cells that express type I IFN receptor type 2
(IFNAR2), and that the expression of IFNAR2 in HCC tissues was
significantly associated with a clinical response to IFN-a/5-FU
therapy, suggesting that IFNAR2 expression might be useful in
predicting the clinical response to such therapy (Ota et al, 2005;
Nagano et al, 2007a). However, even a portion of patients
expressing IFNAR2 showed resistance to the therapy, indicating
the necessity of finding novel biological markers that can more
accurately predict the clinical response to IFN-a/5-FU therapy.
Because the clinical outcome between responders and non-
responders is markedly different, and to avoid the potentially
debilitating adverse effects of this therapy in non-responders,
finding the predictive biomarker is crucial.
In this study, IFN-resistant HCC cell clones were established and
an oligonucleotide microarray analysis was applied to these IFN-
resistant cells and their parental cells. The microarray analysis
identified that insulin-like growth factor (IGF)-binding protein 7
(IGFBP7), which has been reported to have a tumour-suppressive
activity through the induction of apoptosis in some cancers, was a
key gene related to the response to this therapy (Burger et al, 1998;
Landberg et al, 2001; Mutaguchi et al, 2003; Sato et al, 2007; Lin
et al, 2008; Wajapeyee et al, 2008). Furthermore, we confirmed that
IGFBP7 significantly correlated with the response to IFN-a/5-FU
therapy in genetic manipulation experiments and to the clinical
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sresponse in HCC tissue samples. These results indicate that
IGFBP7 could be a suitable marker for predicting the clinical
response to IFN-a/5-FU therapy.
MATERIALS AND METHODS
Cell lines
Human HCC cell lines, PLC/PRF/5 and HLE, were obtained from
the Japan Cancer Research Resources Bank (Tokyo, Japan), and
Hep3B was obtained from the Institute of Development, Aging and
Cancer, Tohoku University (Sendai, Japan). These cells were
maintained in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum, 100Uml
 1 penicillin and 100mgml
 1
streptomycin at 371C in a humidified incubator with 5% CO2 in air.
Establishment of IFN-resistant cells
Parental PLC/PRF/5 cells (PLC-P) were exposed to IFN-a at an
initial concentration of 50IUml
 1. At 2 weeks after exposure,
surviving cells were continuously exposed to sequentially increas-
ing doses of 100IUml
 1 (2 weeks), 200IUml
 1 (2 weeks),
500IUml
 1 (2 weeks), 1000IUml
 1 (2 weeks), and 2000IUml
 1.
Through this process, we successfully established IFN-resistant
cells. By limiting the dilution of the established cells, 10 clones of
PLC/PRF/5 cells resistant to IFN-a were established. The clones
were confirmed as being resistant to IFN-a stably over 20 passages.
Among the 10 clones, three clones (PLC-Rs; PLC-R1, PLC-R2, and
PLC-R3) were used in the experiments of this study.
Drugs and reagents
Purified human IFN-a was kindly supplied by Otsuka Pharma-
ceutical Co. (Tokyo, Japan) and 5-FU and doxorubicin (DXR) by
Kyowa Hakko Kirin Co. (Tokyo, Japan). Cisplatin (CDDP), insulin,
and IGF-1 were purchased from Nippon Kayaku Co. (Tokyo,
Japan), Sigma-Aldrich Co. (St Louis, MO, USA), and Peprotech
(Rocky Hill, NJ, USA), respectively. As for primary antibodies,
polyclonal goat anti-human IGFBP7 antibody and polyclonal
rabbit anti-human IGFBP7 antibody (Santa Cruz Biotechnology
Inc, Santa Cruz, CA, USA) were used for immunohistochemistry
and western blot analysis, respectively. Antibodies to IFNAR2 and
phosphotyrosine (p-Tyr) were purchased from Santa Cruz
Biotechnology Inc; antibodies to signal transducer and activator
of transcription factor (STAT) 1, phosphorylated (Tyr 701) STAT
(pSTAT) 1, Akt, and phosphorylated (Ser 473) Akt were from Cell
Signaling Technology (Beverly, MA, USA); antibodies to STAT2,
pSTAT2, and insulin receptor substrate-1 (IRS-1) were from
Millipore (Milford, MA, USA); and antibody to actin was from
Sigma-Aldrich Co.
Plasmid and transfection
Plasmid coding for short hairpin RNA (shRNA) against IGFBP7
and IGFBP7 expression plasmids was purchased from OriGene
Technologies Inc. (Rockville, MD, USA). They were transfected
into HCC cells using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA) according to the instructions provided by the
manufacturer. After transfection of the shRNA plasmid and
IGFBP7 expression plasmid, stable transfectants were selected
and maintained by adding 1.0mgml
 1 of puromycin (Sigma-
Aldrich Co.) and 600mgml
 1 of G418 (Gibco-BRL, Grand Island,
NY, USA), respectively. The control vector plasmid expressing
non-effective shRNA was similarly introduced into cells to
establish negative control cells for the shRNA plasmid. Empty
vector plasmid was also similarly used to establish negative control
cells for the IGFBP7 expression plasmid. Successful transfection
was confirmed by the coexpression of GFP.
PLC-P transfected by shRNA plasmid against IGFBP7 and by the
negative control vector plasmid was named as PLC-P/shRNA (no. 1
and no. 2) and PLC-P/shRNA-NC, respectively. Short hairpin RNA
no. 1 and no. 2 were different in sequence to shRNA. The PLC-Rs
transfected with the IGFBP7 expression plasmid and the negative
control vector plasmid were named PLC-Rs/IGFBP7 and PLC-Rs/
IGFBP7-NC, respectively.
Patients and specimens
The study subjects were 30 patients with advanced HCC and
recruited as described previously (Nagano et al, 2007a). All
patients had multiple liver tumours in both lobes and tumour
thrombi in the main trunk of the portal vein, and each underwent
palliative reduction surgery with tumour thrombectomy of the
main trunk of the portal vein at the Osaka University Hospital
between October 1999 and December 2004. The IFN-a/5-FU
therapy for remnant multiple liver tumours was applied post-
operatively, as described previously (Ota et al, 2005; Nagano et al,
2007a). Patients were followed up after surgery, with a post-
operative follow-up period of 18.2±19.7 months. Clinical response
to therapy was evaluated according to the criteria of the Eastern
Cooperative Oncology Group (Oken et al, 1982). On the basis of
the clinical response, responders were defined as patients with a
complete response or partial response and non-responders were
defined as patients with a stable disease or progressive disease. The
study protocol was approved by the Human Ethics Review
Committee of Osaka University Hospital and a signed consent
form was obtained from each patient.
Real-time quantitative reverse transcription-PCR
For reverse transcriptase reaction, the extracted RNA, random
hexamers, and Superscript II reverse transcriptase (Invitrogen)
were used according to the instructions supplied by the
manufacturer. Real-time quantitative reverse transcription-PCR
(qRT-PCR) was performed using designed oligonucleotide primers
and Light Cycler (Roche Diagnostics, Mannheim, Germany), and
the amount of target gene expression was calculated. The
expression of the target gene was normalised relative to the
expression of porphobilinogen deaminase (PBGD), which was used
as an internal control. The designed PCR primers were as follows:
IGFBP7 forward primer 50-CTGGGTGCTGGTATCTCCTC-30,
IGFBP7 reverse primer 50-TATAGCTCGGCACCTTCACC-30; PBGD
forward primer 50-TGTCTGGTAACGGCAATGCGGCTGCAAC-30,
PBGD reverse primer 50-TCAATGTTGCCACCACACTGTCCGTCT-30.
Microarray experiments
Microarray experiments were conducted according to the method
described previously (Noda et al, 2009). In brief, total RNA was
purified by TRIzol reagent (Invitrogen) according to the instruc-
tions provided by the manufacturer. The integrity of the purified
RNA was assessed as being of high quality by Agilent 2100
Bioanalyzer (Agilent, Santa Clara, CA, USA) and RNA 6000
LabChip kits (Yokokawa Analytical Systems, Tokyo, Japan). The
purified RNAs obtained from PLC-P, PLC-R1, PLC-R2, and PLC-
R3 were used as samples, and all samples were examined in
duplicate. The samples were mixed and hybridised on a
microarray covering 30336 human probes (AceGene Human
30K; DNA Chip Research Inc and Hitachi Software Engineering
Co, Kanagawa, Japan). The ratio of the expression level of each
gene was converted into a logarithmic scale (base 2) and the data
matrix was normalised. In each sample, genes with missing values
in more than two samples were excluded from the analysis. A total
of 28761 genes out of 30336 genes were finally available for the
analysis.
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Cells grown to semiconfluence were lysed in RIPA buffer (25mM
Tris (pH 7.5), 50mM NaCl, 0.5% sodium deoxycholate, 2% Nonidet
P-40, 0.2% sodium dodecyl sulphate, 1mM phenylmethylsulphonyl
fluoride, 1.6mgml
 1 aprotinin). Western blot analysis was carried
out as described previously (Kondo et al, 2005).
Growth inhibitory assay
The growth inhibitory assay was assessed by the 3-(4-,
5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
(Sigma-Aldrich Co.) assay, as described previously (Eguchi et al,
2000). Briefly, cells were incubated for 72h under several
concentrations of IFN-a and 5-FU. After reincubation for 4h with
MTT solution, acid–isopropanol mixture was added to dissolve
the resultant formazan crystals. The absorbance of the plate was
measured in a microplate reader at a wavelength of 570nm with a
650nm reference, and the results were expressed as a percentage of
absorbance relative to that of untreated controls.
Annexin V assay
The binding of annexin V was used as a sensitive method for
measuring apoptosis, as described previously (Nakamura et al,
2007). At 24h after treatment with IFN-a, PLC-P/shRNA and PLC-
P/shRNA-NC cells were stained by Annexin V-APC and propidium
iodide (PI) (BD Biosciences, Franklin Lakes, NJ, USA), and
analysed on a FACS Aria (BD Biosciences). Annexin V-positive
and PI-negative cells, considered as early apoptotic cells, were used
for the assessment of apoptosis in this study (Lugli et al, 2005).
Measurement of caspase activities
Caspase-3, caspase-8, and caspase-9 activities were measured using
caspase-3, caspase-8, and caspase-9 colorimetric assay kits
(Chemicon International Inc, Temecula, CA, USA). The measure-
ment was performed in cell lysates obtained from each cell 24h
after treatment with IFN-a, using the instructions provided by the
manufacturer.
IRS-1 immunoprecipitation
After incubation for 12h in serum-free medium, cells were
stimulated with 1nM insulin or 10nM IGF-1. The stimulated cells
were lysed in lysis buffer (20mM Tris (pH 7.4), 150mM NaCl, 1.0%
Triton-X-100, 1.0mM EGTA, 1mM phenylmethylsulphonyl fluor-
ide, 1.6mgml
 1 aprotinin, 10mgml
 1 leupeptin). Solubilised
proteins were immunoprecipitated with anti-IRS-1 antibody, and
tyrosine phosphorylation was detected with anti-p-Tyr antibody.
Immunohistochemical staining
Immunohistochemical staining for IGFBP7 in 30 HCC samples was
performed by the method described previously (Kondo et al,
1999). Briefly, formalin-fixed, paraffin-embedded 4mm-thick sec-
tions were deparaffinised in xylene, then treated with an antigen
retrieval procedure and incubated in methanol containing 0.3%
hydrogen peroxide to block endogenous peroxidase. After
incubation with normal protein block serum, the sections were
incubated overnight at 41C with an anti-IGFBP7 antibody as the
primary antibody. Thereafter, the sections were incubated with a
biotin-conjugated secondary antibody (horse anti-goat antibody
for IGFBP7) and with peroxidase-conjugated streptavidin. The
peroxidase reaction was then developed with 0.02% 3, 30-
diaminobenzidine tetrachloride (Wako Pure Chemicals, Osaka, Japan)
solution with 0.03% hydrogen peroxide. Finally, the sections were
counterstained with Meyer’s haematoxylin. The IGFBP7 expression
was defined as the presence of specific staining in the cytoplasm of
cancer cells. Insulin-like growth factor-binding protein 7 expres-
sion was evaluated as positive or negative. Two investigators (Y.T.
and H.E.) independently assessed IGFBP7 expression without
knowledge of the corresponding clinicopathological data. The
assessments were similar by the two investigators for all samples.
Statistical analysis
Data are expressed as mean±s.d. Clinicopathological parameters
were compared using the w
2-test and continuous variables were
compared using Student’s t-test. Survival curves were computed
using the Kaplan–Meier method, and differences between survival
curves were compared using the log-rank test. A P-value o0.05
denoted the presence of a statistically significant difference.
Statistical analysis was performed using StatView (version 5.0,
SAS Institute Inc, Cary, NC, USA).
RESULTS
Characteristics of established IFN-resistant cells
The morphology of PLC-Rs resembled that of PLC-P. Although
PLC-Rs showed similar growth curves compared with PLC-P in the
absence of IFN-a (data not shown), PLC-Rs were significantly
resistant to IFN-a compared with PLC-P, which was confirmed by
MTT assays (Figure 1A). The expression levels of IFNAR2 were not
different between PLC-P and PLC-Rs (Figure 1B). The protein level
of STAT1 and STAT2, which directly bind to the intracellular
domain of IFNAR2 and function as key molecules for signal
transduction, was also not different between PLC-P and PLC-Rs
treated with 1000IUml
 1 of IFN-a for 20min (Figure 1B).
Moreover, the phosphorylation of STAT1 and STAT2 (pSTAT1
and pSTAT2), active forms of STATs, were also not different
between these cells.
IGFBP7 is significantly downregulated in IFN-resistant cells
To investigate the candidate genes involved in the response to IFN-a,
microarray analysis was carried out with PLC-P and PLC-Rs. The
analysis showed that, among the 28,761 genes, 579 (2.0%), 646
(2.2%), and 567 genes (2.0%) altered more than 1.5-fold in
PLC-R1, PLC-R2, and PLC-R3, respectively. As shown in Figure 1C,
107 genes including 92 upregulated genes and 15 downregulated
genes (listed in Supplementary Table S1) were common among the
above 579, 646, and 567 genes. Among these 107 genes, IGFBP7
was identified as one of the most downregulated genes with a
2.963-fold decrease. The downregulation of IGFBP7 in PLC-Rs
compared with PLC-P was validated by real-time qRT-PCR and
western blot analysis (Figure 1D).
Knockdown of IGFBP7 induces resistance to IFN-a
To evaluate the biological effect of IGFBP7, two kinds of plasmids
coding for shRNA against IGFBP7 (no. 1 and no. 2) were
transfected into PLC-P and named as PLC-P/shRNA no. 1 and
PLC-P/shRNA no. 2. The IGFBP7 expression was suppressed at
both mRNA and protein levels in the established PLC-P/shRNAs,
which was confirmed by qRT-PCR and western blot analysis,
respectively (Figure 2A). The MTT assay showed that PLC-P/
shRNAs were significantly more resistant to IFN-a than PLC-P/
shRNA-NC (Figure 2B). On the basis of the measurement of IC50,
the fold increase of IC50 to IFN-a was much larger than that to
other drugs, including 5-FU, CDDP, and DXR, suggesting that
chemoresistance acquired by IGFBP7 is specific to IFN-a (Table 1).
IFNAR2, STAT1, and STAT2 were similarly expressed in PLC-P/
shRNA and PLC-P/shRNA-NC, and the IFN-a-induced pSTAT1
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(Supplementary Figure S1A).
As IGFBP7 has been shown to suppress tumour activity through
induction of apoptosis (Landberg et al, 2001; Mutaguchi et al,
2003; Sato et al, 2007; Wajapeyee et al, 2008), we evaluated the
extent of apoptosis induced at 24h after treatment of PLC-P/
shRNA with 1000IUml
 1 IFN-a. Annexin V assay using flow
cytometry showed a significantly lower percentage of early
apoptotic cells in PLC-P/shRNA than in PLC-P/shRNA-NC
(Figure 3C). Moreover, the activity of caspase-3, caspase-8, and
caspase-9 induced by IFN-a in PLC-P/shRNA was significantly
lower than that by PLC-P/shRNA-NC (Figure 3D). A plasmid
coding for shRNA against IGFBP7 was transfected in other liver
cancer cell lines (HLE and Hep3B). Both these cell lines showed
downregulated IGFBP7 expression (Supplementary Figure S2A).
The transfected HLE and Hep3B cells were also resistant to IFN-a
treatment (500IUml
 1) (Supplementary Figure S2B).
As IGFBP7 has been reported to bind insulin and IGF (Oh, 1998;
Subramanian et al, 2007), it could be conceivable that IGFBP7
induces resistance by interfering with insulin and/or IGF signal-
ling. To verify this possibility, we examined the effect of IGFBP7 on
the phosphorylation of IRS-1 and Akt, major transducers of insulin
and IGF signalling. As shown in Supplementary Figure S1B, there
were no significant differences in the phosphorylation of IRS-1 or
Akt between PLC-P/shRNA and PLC-P/shRNA-NC. This result
suggests that IGFBP7-related resistance occurs in an insulin- and
IGF-independent manner.
Transfection of IGFBP7 restores sensitivity to IFN-a
Next, IGFBP7 expression plasmid was transfected into PLC-R1
(PLC-R1/IGFBP7). Upregulation of IGFBP7 in PLC-R1/IGFBP7
compared with PLC-R1/IFGBP7-NC was confirmed by qRT-PCR
and western blot analysis (Figure 3A). By the MTT assay, PLC-R1/
IGFBP7 partially but significantly restores sensitivity to IFN-a
compared with PLC-R1/IGFBP7-NC (Figure 3B).
IGFBP7 is a useful predictor of clinical response to
IFN-a/5-FU therapy
To confirm whether IGFBP7 expression is associated with the
clinical response to IFN-a/5-FU therapy, HCC samples of 30
patients who underwent IFN-a/5-FU therapy postoperatively were
immunohistochemically stained for IGFBP7 expression. Whereas
the expression levels of IGFBP7 in cancerous lesions varied among
the patients, a homogenous staining for IGFBP7 was observed in
the cytoplasm of cells in non-cancerous sections (Figure 4).
Among the 30 patients examined, 12 (40.0%) showed positive
staining, whereas 18 (60.0%) patients were negative for IGFBP7. Of
the IGFBP7-positive patients, 66.7% (8 of 12) were histologically
evaluated as responders to the therapy, whereas only 11.1% (2 of
18) of IGFBP7-negative patients were responders, suggesting that
IGFBP7 expression was significantly associated with response to
therapy (Po0.05) (Table 2). The sensitivity, specificity, and
accuracy for the prediction to IFN-a/5-FU therapy by IGFBP7
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Figure 1 Characteristics of IFN-resistant PLC/PRF/5 cell clones (PLC-Rs). (A) MTT assay showed that the antitumour effect of interferon-a (IFN-a)i n
PLC-Rs was significantly lower than that in parental PLC/PRF/5 cells (PLC-P). Data are mean±s.d. *Po0.05 compared with PLC-P. (B) Western blot
analysis revealed that the expression levels of type I IFN receptor type 2 (IFNAR2), signal transducer and activator of transcription factor 1 (STAT1), STAT2,
phosphorylated STAT1 (pSTAT1), and pSTAT2 were similar in PLC-P and PLC-Rs. (C) Schematic of the results of the performed microarray analysis and
identified 107 genes. The 107 genes were up- or downregulated by more than 1.5-fold and were commonly identified in the three types of cells.
(D) Quantitative reverse transcriptase-PCR and western blot analysis confirmed the significant suppression of insulin-like growth factor-binding protein 7
(IGFBP7) expression in PLC-Rs compared with PLC-P. Data are mean±s.d. *Po0.05.
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of the other clinicopathological factors tested, apart from IFNAR2,
were associated with response to the therapy (Supplementary
Table S2).
Finally, we examined the correlations between postoperative
prognosis and various clinicopathological factors including
IGFBP7 status. The postoperative overall survival in IGFBP7-
positive patients was significantly better than that in IGFBP7-
negative patients (Po0.05, Figure 5). Furthermore, multivariate
analysis of overall survival using two significant factors identified
in the univariate analyses showed that, in addition to IFNAR2,
IGFBP7 status was an independent and significant determinant of
overall survival (Table 3), indicating that IGFBP7 is a potentially
useful marker for the prediction of clinical response to IFN-a/5-FU
therapy.
DISCUSSION
In this study, gene expression profiling identified significant
suppression of IGFBP7 in PLC-Rs compared with PLC-P. Insulin-
like growth factor-binding protein 7, also known as IGFBP-rP1 and
MAC25, can inhibit the proliferation of cancer cells, and its
expression is downregulated in certain cancers (Burger et al, 1998;
Landberg et al, 2001; Mutaguchi et al, 2003; Sato et al, 2007;
Lin et al, 2008; Wajapeyee et al, 2008). It is also reported that
IGFBP7 suppression is associated with rapid tumour growth and
tumour invasiveness (Burger et al, 1998; Sato et al, 2007; Lin et al,
2008). However, there are no reports of the association between
IGFBP7 expression and sensitivity to chemotherapeutic drugs.
In this study, IGFBP7 was suppressed by shRNA transfection in
HCC cells and the transfected cells acquired resistance to IFN-a.
The association between IGFBP7 expression and response to IFN-a
was also confirmed in experiments using IGFBP7-overexpressing
cells. Considering that IGFBP7-suppressed cells showed a smaller
percentage of apoptosis than control cells, the acquired resistance
was thought to result from the impediment of apoptosis. The
suppression of apoptosis by downregulation of IGFBP7 was
consistent with that found in previous studies (Burger et al,
1998; Landberg et al, 2001; Mutaguchi et al, 2003; Sato et al, 2007;
Lin et al, 2008; Wajapeyee et al, 2008). In addition to resistance to
IFN-a, IGFBP7-suppressed cells showed modest but significant
resistance to other drugs. Taking into consideration the fact that
IGFBP7 promotes apoptosis even in the absence of any drugs,
the acquisition of resistance to both IFN-a and other drugs may be
quite natural. However, the fold increase in acquired resistance to
IFN-a was much larger than that to other drugs as confirmed by
measurements of IC50, suggesting that IGFBP7 is specifically
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shRNA-NC. (D) The activity of caspase-3, caspase-8, and caspase-9 induced by IFN-a in PLC-P/shRNA was significantly lower than that in PLC-P/shRNA-NC.
Data are mean±s.d. *Po0.05.
Table 1 IC50 for IFN-a, 5-FU, CDDP, and DXR in PLC-P/shRNA-NC
and PLC-P/shRNA
IC50
Drug
PLC-P/
shRNA-NC
PLC-P/
shRNA
Fold increase
(shRNA/shRNA-NC)
IFN-a (IUml
 1) 807±96.5 11608.0±1179.4 14.38
5-FU (mgml
 1) 41.4±5.5 53.1±10.3 1.28
CDDP (mgml
 1) 3.9±0.3 4.8±0.4 1.24
DXR (mgml
 1) 1.4±0.2 2.2±0.4 1.52
Abbreviations: 5-FU¼5-fluorouracil; CDDP¼cisplatin; DXR¼doxorubicin; IC¼
inhibitory concentration; IFN-a¼interferon-a;N C¼negative control; PLC-P¼Parental
PLC/PRF/5 cell; sh-RNA¼short hairpin RNA. Data are mean±s.d.
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srelated to the resistance to IFN-a. Moreover, from the experiments
of insulin- and IGF signalling, this effect of IGFBP7 was suggestive
to occur in an insulin- and IGF-independent manner.
Furthermore, to clarify the mechanism of IGFBP7-specific IFN
resistance, we examined IFNAR2 expression and IFN signalling
and compared them between PLC-P and PLC-Rs and between PLC-
P/shRNA and PLC-P/shRNA-NC. The IFN signalling was evaluated
by the expression of STAT1 and STAT2, and by IFN-a-induced
expression of pSTAT1 and pSTAT2. The results showed no
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Figure 3 Characteristics of IFN-resistant PLC/PRF/5 cell clones (PLC-R1) transfected with Insulin-like growth factor-binding protein 7 (IGFBP7) expression
plasmid. (A) Quantitative reverse transcriptase-PCR and western blot analysis showed that the IGFBP7 expression level in PLC-R1/IGFBP7 was significantly
higher than that in PLC-R1/IGFBP7-negative control (NC). (B) MTT assay showed that PLC-R1/IGFBP7 were significantly more sensitive to IFN-a than was
PLC-R1/IGFBP7-NC. Data are mean±s.d. *Po0.05.
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T
N
Figure 4 Immunohistochemistry for Insulin-like growth factor-binding protein 7 (IGFBP7) in representative hepatocellular carcinoma cases
(A) A representative IGFBP7-positive case. The IGFBP7 expression was shown in the cytoplasm of normal liver cells and in the majority of tumour
cells. (B) A representative IGFBP7-negative case. The IGFBP7 expression was not identified in tumour cells. Upper panel, low-power field (Bar¼200mm);
lower panel, high-power field (Bar¼50mm); T, tumour lesion (arrowheads); N, non-tumour lesion.
Table 2 Association between immunohistochemically determined
IGFBP7 expression and clinical response to IFN-a/5-FU therapy
Responders Non-responders P-value
IGFBP7(+) 8 4
0.0057 IGFBP7( )2 1 6
Abbreviations: 5-FU¼5-fluorouracil; IFN-a¼interferon-a; IGFBP7¼insulin-like
growth factor-binding protein 7.
IGFBP7 and response to IFN-based therapy in HCC
Y Tomimaru et al
1488
British Journal of Cancer (2010) 102(10), 1483–1490 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
ssignificant differences in the expression of IFNAR2 and IFN
signalling between PLC-P and PLC-Rs or between PLC-P/shRNA
and PLC-P/shRNA-NC. On the other hand, Wajapeyee et al (2008)
reported that IGFBP7 induces apoptosis through increased
SMARCB1 upregulation by the recruitment of STAT1 to the
binding site of the SMARCB1 promoter. Another study reported
that STAT1 is recruited to the SMARCB1 promoter by IFN,
suggesting that IFN-induced STAT1 recruitment to the SMARCB1
promoter is possibly one of the mechanisms of IFN-induced
apoptosis (Hartman et al, 2005). It might therefore be possible that
STAT1 recruitment could be prevented antagonistically when
IGFBP7 is suppressed, leading to a higher resistance to IFN-a than
to other drugs. In this study, however, pSTAT1 expression was not
different between PLC-P and PLC-Rs or between PLC-P/shRNA
and PLC-P/shRNA-NC, and there were no significant differences in
the SMARCB1 expression evaluated by the result of microarray
between PLC-P and PLC-Rs. These results indicate that IGFBP7-
related IFN resistance is based not on SMARCB1 but on a novel
mechanism, which should be clarified in the future.
The present study revealed that, in addition to the significant
association between IGFBP7 status and the clinical response to
IFN-a/5-FU therapy, the IGFBP7 status as well as IFNAR2, was
an independent prognostic factor in HCC patients undergoing
IFN-a/5-FU therapy. Because our 30 patients in this study are those
with far advanced HCC, it is quite reasonable that the clinical
response to the therapy correlates well with the prognosis after the
therapy. These results indicate that prediction of response and
prognosis by evaluating IGFBP7 and IFNAR2 is useful in this
clinical setting.
In summary, IGFBP7 was selected on the basis of the results
of the microarray analysis using established IFN-resistant HCC
cell lines. The expression of IGFBP7 in tumour tissue correlated
significantly with the response to IFN-a/5-FU therapy. This
correlation was also confirmed in genetic manipulation ex-
periments. Our findings suggest that IGFBP7 could be a novel
marker for the prediction of the clinical response to IFN-a/5-FU
therapy.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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